Shen Shen

Shen Shen is a Senior Director at Vertex Pharmaceuticals, specializing in gene editing and delivery technologies. With over 15 years of research and development experience in gene therapy and gene editing, Shen has worked extensively in both academic and industry environments.

Professional Background

• Current Role: Senior Director, AAV Technologies at Vertex Pharmaceuticals since December 2021.
• Previous Experience:
  • Scientist I-III and Program Lead in Molecular Biology at Editas Medicine from September 2014 to January 2019.
  • Postdoctoral Researcher at the Salk Institute for Biological Studies from August 2013 to August 2014.

Expertise

Shen has a robust background in drug development within genomic medicine, focusing on:

• Gene Delivery Technologies: Proficient in adeno-associated virus (AAV), lentiviral vectors, and lipid nanoparticles.
• Research Contributions: Authored and co-authored four US patents, over ten scientific articles, and presented at more than ten international conferences.
• Team Leadership: Experienced in building and managing cross-functional teams for early development projects.

Education and Certifications

Shen holds a postgraduate certificate in Clinical Pharmacology, Drug Development, and Regulation from Tufts Center for the Study of Drug Development, issued in February 2017.

Languages

Fluent in both Mandarin Chinese and English.

Shen's extensive experience positions them as a significant contributor to advancements in gene therapy and genomic medicine at Vertex Pharmaceuticals.